CAMERON DURRANT MD
CHAIRMAN AND CHIEF EXECUTIVE OFFICER, KALOBIOS 

Dr. Cameron Durrant is the Chairman and Chief Executive Officer of KaloBios, since March 1, 2016. He was elevated to that position after serving on the board of directors since January 7, 2016. Dr. Durrant’s expertise and business career has revolved around transformations, whether for brands, business units, or small companies. He has particular therapeutic experience in infectious diseases, pediatrics and oncology – coupled with experience as a practicing physician. He has served as board chairman, lead independent director and operated as CEO for several specialty pharma companies/biotechs in both the private and public sector. 


                HOME        |         CONFERENCE AGENDA         |          SPEAKERS          |         DEAL OF THE YEAR        |          REGISTER           |      CONTACT US
What makes Allicense different from other conferences? Experience. Our mission is to bring together industry pros to explore the latest trends and tools. Together with 200+ dealmakers, we’ll learn how to make better more quantifiable deals. To accomplish this mission, Thomson Reuters serves as a catalyst for discussion, learning and innovation. Meet the speakers driving our discussion. 
ALLICENSE 2015 SPEAKERS INCLUDED

•   George Golumbeski, Celgene
•   Will Roberts, President, TesoRx
•   Steve Engen, Vice President Japan, Locust Walk Partners
•   Osama Nabulsi, Vice President Business Development     & Alliance Management, Hikma Pharmaceuticals
•   Doug Fisher, Peter Michael Foundation
•   Jay Mohr, Managing Director, Locust Walk Partners
•   Bob Moore, Gates Foundation
•   Josh Hamermesh, Vice President, Locust Walk     Partners
•   Joshua Salisbury—CEO, Salisbury Capital Markets
•   Sara Radcliffe, CEO California Biomedical Innovation     Alliance
•   Jon Norris, Managing Director, SVB Capital
JONATHAN NORRIS
MANAGING DIRECTOR
SVB HEALTHCARE

Jonathan Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations. 

In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than sixteen years of banking experience working with healthcare companies and venture capital firms. 

Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University. 

CHEN YU
MANAGING PARTNER, VIVO

Chen Yu, M.D., M.B.A. is a Managing Partner based in Palo Alto who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Most recently, Dr. Yu served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which partners with leading companies across Asia and Europe. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Sentre Heart (US), Rempex (Acquired by MDCO for $474 MM), Nora Therapeutics (US), Jian Rui Bao (China), GMT Medical (China), and Synaptic Medical (China). Other representative investments include Trauson (acquired by Stryker for $764 MM), Durata (DRTX), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX). 

Dr. Yu is also active in the community and currently serves on the California Leadership Council for the Nature Conservancy, an environmental non-profit with global reach. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.
CLIFFORD J. STOCKS
FOUNDER AND CHIEF EXECUTIVE OFFICER, ONCORESPONSE

Clifford J. Stocks is the Founder and Chief Executive Officer of OncoResponse, Inc. Recently he was CEO of Theraclone Sciences and formed OncoResponse through a strategic alliance between Theraclone and MD Anderson Cancer Center. Previously he helped form and served as Chief Business Officer of Calistoga Pharmaceuticals, Inc. At Calistoga he led the partnering and M&A processes, activities and teamwork that resulted in the acquisition of Calistoga in 2011 by Gilead for $600 million. Mr. Stock's career includes 15 years at ICOS Corporation, where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and he was a key architect of the Lilly ICOS joint venture partnership leading to their $2.3 billion merger in 2007. Previously in his career, Mr. Stocks was a management consultant in the Health Services practice of Booz, Allen & Hamilton, and his early career includes academic research on staff in the department of immunology at the University of Utah and on staff in the department of molecular genetics and cell biology at the University of Chicago, where he also received an MBA degree from the University of Chicago Booth Graduate School of Business.

AMY BRICKER
VICE PRESIDENT, SUPPLY CHAIN STRATEGY, EXPRESS SCRIPTS

Amy Bricker is responsible for key relationships and strategic initiatives across the pharmaceutical supply chain, including manufacturers and retail providers, which create value and savings for Express Scripts’ clients and keep medicine within reach of patients. 
In addition to managing the supply chain, she also supports the company’s efforts to educate legislators about the value of pharmacy benefit management. During her five years at Express Scripts, Amy has held leadership roles in pharmacy network management, supply chain economics and retail contracting and strategy.

Prior to joining the company, she served Walgreens Health Services as regional vice president of account management and director of health initiatives clinical sales. Her earlier retail pharmacy career included positions with BJC Healthcare and Walgreen Company.

Amy holds a bachelor’s of science degree in pharmacy from the St. Louis College of Pharmacy. She also serves on the boards of two nonprofit organizations: Memory Care Home Solutions and Youth in Need.

MONA WAN,
ASSOCIATE DIRECTOR, STANFORD'S OFFICE OF TECHNOLOGY LICENSING

Mona Wan is an Associate Director at Stanford’s Office of Technology Licensing (OTL) and has been with the office for 10 years in total.  At OTL she manages technologies in both the life sciences and high tech area, from evaluation through licensing.  She is a member of the OTL Executive Committee responsible for shared governance of the office.  Prior to her latest tenure at Stanford’s OTL, Mona worked as a consultant for a variety of life sciences companies in business development, IP and contracts management and project management.  Some of her clients included Cellgate, Cyterix Pharmaceuticals, On-Q-ity, and Microsonic Systems.  
Mona received her B.S. in Chemical Engineering from MIT, M.S. in Chemical Engineering from Stanford and MBA from Stanford.
LAURA VITEZ
PRINCIPAL BUSINESS ANALYST, THOMSON REUTERS

Laura Vitez has over 25 years of experience in the life sciences industry. She has held lead and advisory business development roles at companies including multiple small biotechs, a mid-sized pharma, and two consulting firms. Ms. Vitez has participated in alliances generating more than $2 billion in reported value for her clients and companies. She holds an MS in Biochemistry and a BA in Mathematics and Chemistry. She joined Thomson Reuters Recap in the fall of 2013.

DONALD JOHNSTON
SENIOR DIRECTOR, THOMSON REUTERS

Donald Johnston is Senior Director, Current Awareness, in the IP & Science unit of Thomson Reuters. He works directly with the editorial team at our two award-winning online news services, BioWorld Today and Medical Device Daily, as well as with marketing and sales, to create or adapt indispensable industry content for use on internal and external blogs, promotional websites and to be shared via social media
DAVID DUNN
US PRACTICE LEAD & SCIENTIFIC ADVISOR FOR PORTFOLIO AND LICENSING; 
LIFE SCIENCES, PROFESSIONAL SERVICES,
THOMSON REUTERS

David Dunn has over 20 years of experience in the pharmaceutical and biotechnology industries and currently works with clients on a broad array of assignments including competitive landscape analysis, drug and target portfolio evaluation, technology assessment, industry trends and the application of Big Data in guiding scientific and business strategy.  He is a recognized expert in business and scientific trends in the biosimilars industry and has published on the subject.
RICHARD SOLL
SENIOR VICE PRESIDENT, INTERNATIONAL DISCOVERY SERVICE UNIT (IDSU) AT WUXI APPTEC

Dr. Richard Soll is Senior Vice President, International Discovery Service Unit (IDSU) at WuXi AppTec  and  leads the WuXi offices in Cambridge, Massachusetts and in Israel to bring WuXi’s comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world’s two leading biotech hubs.
Dr. Soll’s contributions to drug discovery and development led to the discovery of the HCV breakthrough therapy elbasvir, the JAK2 inhibitor fedratinib, and more than 10 other clinical stage drugs.  Dr. Soll has co-authored more than 100 patents and papers. Dr. Soll serves on the board of the Accelerator snf has been an SAB member to biotech companies and advisor to entrepreneurs.

Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals, and was trained as a synthetic chemist at Dartmouth and Harvard. 

KENT HAWRYLUK
CHIEF BUSINESS OFFICER, AVIDITY NANOMEDICINES, LLC. 

P. Kent Hawryluk is the Chief Business Officer of Avidity NanoMedicines LLC, a company advancing antibody-siRNA conjugates (ASC™). He was also Co Founder of MB2 LLC, a clinical stage company focused on diabetes and obesity, and served as its Chief Executive Officer from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Previously, Mr. Hawryluk co founded Marcadia Biotech Inc, and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia was acquired by Roche Holding Ltd. in December 2010. He currently serves as partner of Twilight Venture Partners, LLC, a private seed and early stage life science venture capital fund, and as a director of Gemphire Therapeutics Inc., a clinical-stage cardiovascular drug company. Mr. Hawryluk holds a B.A. from Princeton University, an M.B.A. from Kellogg School of Management at Northwestern University, and an M.S. degree in biology from Indiana University Purdue University Indianapolis. 
ARTHUR SANDS
CHIEF EXECUTIVE OFFICER, NURIX

Arthur T. Sands, M.D., Ph.D. has served as the Chief Executive Officer at Nurix and as a member of the company’s board of directors since September, 2014. In September, 2015 Dr. Sands and his management team completed a strategic collaboration with Celgene for the discovery, development and commercialization of novel small molecule therapeutics in oncology, inflammation and immunology that included an upfront payment of $150 million and significant milestones, royalties and options for commercialization of drugs. Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals and served as President, Chief Executive Officer and a Director from 1995 to 2014. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company, catalyzed by numerous alliances with Bristol Myers Squibb, Takeda and Genentech, and generating more than $450 million in revenue. Dr. Sands also serves as Adjunct Professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. He has also published many scientific and medical articles and is an inventor on numerous patents related to the discovery of human genes and their use in the development of new therapies. Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University. 
JUNE LEE
DIRECTOR OF EARLY TRANSLATIONAL RESEARCH, UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE

June Lee, MD, is the Director of Early Translational Research and the Catalyst Program at the UCSF Clinical and Translational Science Institute (CTSI) as well as a Professor in the School of Medicine. A key focus of her work at UCSF is to identify the most compelling discovery research and enabling and supporting the projects towards product and commercialization. She is the chief architect of the highly successful Catalyst Program, which serves as an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. She also oversees key strategic partnerships at UCSF to include industry collaborations. Currently, she also serves as Chair of the Drug, Device, Discovery and Development (D4) workgroup of UC BRAID (University of California Biomedical Research Acceleration Integration and Development) and was previously the Vice-Chair of CTSA Translational Key Function Committee. 
 
Prior to UCSF, she worked at Genentech where as the therapeutic area head, she led early clinical development programs in Infectious Diseases, Cardiovascular/Metabolic Diseases, and Respiratory Diseases. In that role, she was responsible for the clinical strategy and execution of programs in the early clinical development stages and successfully developed pre-clinical and late stage research projects in a variety of therapeutic areas through IND clearance and early stage clinical proof of concept studies.

BEN THORNER,
VICE PRESIDENT, MERCK RESEARCH LABORATORIES

Ben Thorner is Vice President, BD&L and Head of North American Innovation Hubs at Merck Research Laboratories.  As such, Ben leads the Boston Innovation Hub and the West Coast Innovation Hub, each of which is a full business development organization, tasked with bringing new molecules, technologies and collaborations into Merck, especially in the New England and West Coast Regions.  The emphasis for these activities is on early-stage (prior to PoC in Humans) opportunities.  The Innovation Hubs work closely with academic centers, biotech and pharma companies. 
Prior to joining Merck, Ben was Head of Transactions in Strategic Alliances at Novartis Institutes for BioMedical Research (NIBR).  In this role, Ben led a group of professional negotiators to value and structure deals and to drive cross-functional deal teams to close deals between NIBR (Novartis’ organization responsible for Research and Early Development) and potential partners.  These deals ranged from research collaborations, to licensing deals to IP acquisitions and the like.  NIBR’s partners include biotechnology companies and academic partners.
Prior to joining Novartis, Ben led the execution of numerous deals as Executive Director of Licensing at Amgen.  Ben also held other roles at Amgen, including Senior Counsel in Amgen’s legal department, where he drafted and negotiated key licensing and related deals.  
Before moving in-house, Ben worked as an attorney in private practice at the law firm of Brobeck, Phleger & Harrison LLP, spending several years in the firm’s offices in New York City and in the Boulder/Denver area of Colorado.  Ben also served as a law clerk to the Honorable Judge Randall R. Rader on the US Court of Appeals for the Federal Circuit in Washington DC. 
Ben holds a Masters Degree in Biology and a JD from the University of Virginia and an undergraduate degree in Government & Politics from George Mason University.  

DOTY SPEAKERS

We are thrilled to have representatives from the buyside and sellside of each of the 10 nominated deals (5 M&A and 5 licensing transactions) present during the Allicense 2016 Breakthrough Deal of the Year Nominees rapid-fire presentation scheduled for 2:15 – 3:15 PM. Nominees were announced May 3. Click here to meet the representatives. 

PETER KOLCHINSKY, PhD
MANAGING PARTNER AND PORTFOLIO MANAGER, RA CAPITAL MANAGEMENT

Peter Kolchinsky is a founder, Managing Director, and Portfolio Manager at RA Capital Management, a crossover fund manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a member of the Board of Directors of Dicerna Pharmaceutics, Wave Life Sciences, and a number of private companies. Peter also leads the firm’s outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers, and industry.  He authored “The Entrepreneur’s Guide to a Biotech Startup” and served on the Board of Global Science and Technology for the National Academies of Sciences. Peter received a Bachelor’s degree from Cornell University and a PhD in Virology from Harvard University.

TOM DULEY
PARTNER, KING & SPALDING'S CORPORATE PRACTICE GROUP

Tom Duley is a partner in King & Spalding’s Corporate Practice Group in San Francisco and concentrates his practice on technology transactions for life sciences clients. Mr. Duley negotiates, drafts and manages intellectual property and commercial transactions. He has worked with clients throughout the corporate lifecycle, from startup entities obtaining their first university in-license to large public corporations restructuring their product holdings. He was previously Senior Corporate Counsel of PDL BioPharma, Inc., when it was a fully integrated biopharmaceutical company. He later advised PDL BioPharma on its spin-out of Facet Biotech. Mr. Duley is also an Adjunct Professor at UC Hastings College of the Law, where he teaches a course in international business negotiations; and has been featured as a Life Sciences Star twice by LMG Life Sciences.
JOHN MULLIGAN
FOUNDER AND CEO, GOOD THERAPEUTICS, INC.

Dr. John Mulligan is the Founder and CEO of Good Therapeutics, Inc., a company developing self-regulating drugs that act only when they are needed.  Dr. Mulligan led the early-stage research on two drug candidates, an antibody for osteoporosis that is in Phase III trials at Amgen and a glucose-responsive insulin that is in pre-clinical development at Eli Lilly.  He founded Glycostasis to develop the glucose-responsive insulin, invented the core technology, and led the business development effort that culminated in the acquisition of Glycostasis by Eli Lilly.  Prior to Glycostasis and Good Therapeutics, Dr. Mulligan co-founded two synthetic biology companies and led the Genomics group at Darwin Molecular.  He is an inventor on 23 issued patents that include an antibody therapeutic, novel drug targets, software, two laboratory instruments, DNA synthesis methods, and a new class of reporter molecules for multiplexed analyte detection.  Dr. Mulligan was trained in genetics at MIT and Stanford, did a post-doctoral fellowship with Ron Davis, and was a Research Assistant Professor at the Stanford Medical School. 

DANIEL J. ESTES
PRINCIPAL, FRAZIER HEALTHCARE PARTNERS

Dan Estes joined Frazier Healthcare Partners in 2011 and is currently a Principal on the Frazier Life Sciences team, focusing on investments primarily in Seed and Series A biopharmaceutical companies. He serves on the boards of Semnur Pharmaceuticals and Outpost Medicine, and he has also been involved in Frazier’s investments in Acerta (acquired by AstraZeneca), Cidara (NASDAQ: CDTX), ProNAi (NASDAQ: DNAI), Tobira (NASDAQ: TBRA), Precision Dermatology (acquired by Valeant), Calibrium (acquired by Novo) and others.

Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised global pharmaceutical and biotechnology companies on R&D strategy and business development strategy.

Dan received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on studying the roles of potassium ion channels on human T cells in human autoimmune diseases.  He also holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.

TRICIA MULLINS
VP, STRATEGIC ALLIANCES, GLOBAL GENES

Tricia Mullins joins Global Genes as Vice President, Strategic Alliances after working in the biotech arena for 20 successful years.  Tricia has held instrumental leadership roles in sales, marketing, management, patient advocacy and new business development creating programs and platforms in rare diseases, chronic diseases and conditions critical to public health priorities.  Tricia has extensive strategic experience with nine biotech launches, three of which in the orphan disease space.  Tricia’s passion is patients and bringing new innovative solutions to biotech industry partners, community organizations, patient organizations, as well as patients and their families.

Tricia is a native New Yorker, who would rather walk 30 “blocks” than wait for a taxi, unless it is raining of course!  She holds a BS in Business and Communications from Saint John’s University.  When Tricia isn’t working, she enjoys yoga, traveling to far away places, pursuing her Master’s in Public Health and watching her beloved Big East St. John’s Basketball team!  She is the proud Aunt to Kate, Taylor and Ava.
KARL HANDELSMAN 
FOUNDER, CODON CAPITAL

Karl invests in early stage therapeutic and synthetic biology startups.  Four of his most recent investments exited in under 18 months, three other seed/series A investments have had follow on rounds at over a five fold step up, and one of them will market engineered spider silk in high performance consumer products next year.

Karl has invested in over three dozen companies with exits via IPO and acquisition.  Prior to becoming a venture investor Karl worked in business development at two companies which were both acquired for billions of dollars.

SIMEON GEORGE, M.D.
PARTNER, S.R. ONE, LIMITED

Simeon joined SR One in 2007 and leads SR Ones investment activities on the West Coast. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.

Simeon received his BA in Neuroscience from the Johns Hopkins University, where he graduated Phi Betta Kappa. Simeon received his MD from the University Of Pennsylvania School Of Medicine and his MBA (Mayer Scholar) from the Wharton School of the University of Pennsylvania.

Simeon is a member of the Board of Directors of Bird Rock Bio, Crispr Therapeutics, Effector Therapeutics, Principia Biopharma and Progyny. He served as a Director of Genocea Biosciences (GNCA), HTG Molecular (HTGM), and Semprus Biosciences (acquired by Teleflex).
ANITA J. CHAWLA
MANAGING PRINCIPAL, ANALYSIS GROUP

Dr. Chawla has more than 25 years of experience as an economist in the health care sector. In her work, Dr. Chawla has assessed the value of a wide range of therapies to inform health care decision makers. Since joining Analysis Group in 2007, she has helped life sciences manufacturers and development-stage companies address product development and commercialization objectives, particularly as they relate to product value and market access. Her recent client work includes evidence generation to support pricing and reimbursement in the context of market access and launch strategy, and forecasts to support licensing and venture funding discussions. Dr. Chawla’s recent publications include an assessment of the impact of regulatory requirements for cardiovascular risk evaluation for diabetes therapies; as well as an evaluation of the impact of risk and associated cost of product safety litigation, including potential product withdrawal, on weight management drug development decisions. She has served as a reviewer or referee for several journals, including Value in Health, Health Affairs, Health Services Research, Journal of the American Medical Association, and Journal of Business and Economic Statistics. Prior to joining Analysis Group, she was head of the health economics and outcomes research department at Genentech, Inc.

CHRISTOPHER J. DENN
PARTNER, GOODWIN PROCTER

Chris Denn, a partner in Goodwin Procter’s Life Sciences Practice, assists boards of directors and management teams in navigating the wide variety of commercial and legal issues that are critical to the success of a company’s efforts to deliver new treatments to patients. Mr. Denn has a comprehensive understanding of the life science industry informed by years spent as an in-house lawyer at AstraZeneca and extensive experience in private practice advising clients ranging from start-up companies to mid-cap public companies.